DaVita Inc.
DVA
Rang in Aktien
#1799
DaVita Inc. specializes in delivering essential kidney dialysis treatments and... DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Aktienkurs
$186.81
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$11.92B
Veränderung (1 Tag)
-1.10%
Veränderung (1 Jahr)
48.40%
Land
US
Handel DaVita Inc. (DVA)
Kategorie
Healthcare
EPS für DaVita Inc. (DVA)
EPS zum June 2026 TTM: $11.63
Laut den aktuellen Finanzberichten und dem Aktienkurs von DaVita Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $11.63. Am Ende des Jahres 2024 betrug das EPS $11.02 ein Rückgang im Vergleich zu dem EPS von 2023, das $7.62 betrug.
EPS-Verlauf von DaVita Inc. von 2000 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $11.63 | 15.61% |
| 2025 | $10.06 | -8.71% |
| 2024 | $11.02 | 44.62% |
| 2023 | $7.62 | 29.59% |
| 2022 | $5.88 | -36.77% |
| 2021 | $9.30 | 42.20% |
| 2020 | $6.54 | 23.63% |
| 2019 | $5.29 | 14.25% |
| 2018 | $4.63 | 31.53% |
| 2017 | $3.52 | -19.27% |
| 2016 | $4.36 | 243.31% |
| 2015 | $1.27 | -62.76% |
| 2014 | $3.41 | 12.91% |
| 2013 | $3.02 | 8.24% |
| 2012 | $2.79 | 10.71% |
| 2011 | $2.52 | 26.00% |
| 2010 | $2.00 | -1.96% |
| 2009 | $2.04 | 14.61% |
| 2008 | $1.78 | -1.11% |
| 2007 | $1.80 | 28.57% |
| 2006 | $1.40 | 23.89% |
| 2005 | $1.13 | 0.00% |
| 2004 | $1.13 | 21.51% |
| 2003 | $0.93 | 27.40% |
| 2002 | $0.73 | 32.73% |
| 2001 | $0.55 | 898.19% |
| 2000 | $0.06 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $29.96 | 157.61% |
US
|
|
| - | - |
DE
|
|
| $26.12 | 124.59% |
US
|
|
| $1.84 | -84.16% |
SA
|
|
| - | - |
MY
|
